Efficacy of AesyBite Active in Reducing Sleep Bruxism Activity

Sponsor
Aesyra SA (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06153810
Collaborator
(none)
26
1
2
11.5
2.3

Study Details

Study Description

Brief Summary

The overall objective of the clinical investigation is to evaluate whether the use of the AesyBite Active reduces the bruxism activity.

Condition or Disease Intervention/Treatment Phase
  • Device: Biofeedback stimulation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
26 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of AesyBite Active in Reducing Sleep Bruxism Activity
Actual Study Start Date :
Nov 17, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Oct 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Early stimulation

Biofeedback treatment is started after two weeks of observation

Device: Biofeedback stimulation
Delivery of the vibratory biofeedback stimulus

Experimental: Delayed stimulation

Biofeedback treatment is started after three weeks of observation

Device: Biofeedback stimulation
Delivery of the vibratory biofeedback stimulus

Outcome Measures

Primary Outcome Measures

  1. Reduction of the bruxism activity [1 month]

    Evaluation of the efficacy of AesyBite Active in reducing the bruxism activity expressed as total sleep bruxism duration per hour (TDPH, sec/hour) by at least 60% in the stimulation phase compared with baseline with a 10% non-inferiority margin.

Secondary Outcome Measures

  1. Reduction of the bruxism index [1 month]

    Evaluation of the efficacy of AesyBite Active in reducing the bruxism index expressed as number of sleep bruxism episodes per hour (episodes/hour).

  2. Reduction of the mean duration of sleep bruxism episode [1 month]

    Evaluation of the efficacy of AesyBite Active in reducing the mean duration of sleep bruxism episodes (sec/episode).

  3. Relative change in average intensity of bruxism episodes [1 month]

    A measure of the average bite strength exerted during the bruxism episodes.

  4. Change in self-reported sleep quality marked on a visual analogue scale [1 month]

    Change in self-reported sleep quality assessed using a visual analogue scale (VAS) with a sleep quality scale from 0 to 10.

  5. Change in self-reported pain marked on a visual analogue scale [1 month]

    Change in self-reported pain (facial pain, myofascial headache) assessed using a visual analogue scale (VAS) with a pain severity scale from 0 to 10.

  6. Change in self-reported comfort marked on a visual analogue scale [1 month]

    Change in self-reported comfort assessed using a visual analogue scale (VAS) with a comfort severity scale from 0 to 10.

  7. Change in self-reported retention marked on a visual analogue scale [1 month]

    Change in self-reported retention assessed using a visual analogue scale (VAS) with a retention severity scale from 0 to 10. 1 month

  8. Change in self-reported ease of breathing marked on a visual analogue scale [1 month]

    Change in self-reported ease of breathing assessed using a visual analogue scale (VAS) with a ease of breathing severity scale from 0 to 10.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 to 70 years, in good general health.

  • Presence of at least one of the following:

  • sleeping partner's report of tooth grinding sounds during sleep for at least three nights per week within the last 6 months,

  • hypertrophy of the masseter muscle upon digital palpation.

  • Presence of at least one of the following:

  • signs of tooth attrition or shiny spots on dental restorations,

  • self-report of masticatory muscle fatigue or pain at awakening.

  • Previous prescription of a night splint for bruxism.

  • Able to understand and follow the protocol and complete the self-administered paper questionnaires.

  • Able to provide written informed consent to study participation and storage and processing of study data

Exclusion Criteria:
  • Allergic to Ethylene-Vinyl Acetate (EVA) copolymer.

  • With more than two missing molars (excluding third molars).

  • Ongoing orthodontic treatment (e.g. teeth alignment).

  • With major neurological or psychiatric disorders including substance dependence.

  • Using a removable dental prosthesis.

  • Using a medication with known effects on sleep or motor behavior.

  • Suffering from periodontal disease.

  • With occlusal or jaw abnormalities that prevent the wearing of a normal dental splint.

  • Participants with pacemakers.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione Irccs San Gerardo Dei Tintori Monza Monza E Brianza (MB) Italy 20900

Sponsors and Collaborators

  • Aesyra SA

Investigators

  • Principal Investigator: Marcello Maddalone, Fondazione IRCCS San Gerardo dei Tintori

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Aesyra SA
ClinicalTrials.gov Identifier:
NCT06153810
Other Study ID Numbers:
  • ABA020-CIP-001
First Posted:
Dec 1, 2023
Last Update Posted:
Dec 1, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 1, 2023